Pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
To explore novel treatment/prevention of COVID-19, a novel broad-spectrum neutralizing antibody injection, anti-SARS-CoV-2 antibody SA55 Injection (SA55 injection) was developed. Pharmacokinetics (PK) characteristics of SA55 injection were evaluated in a randomized, controlled, double-blind phase □ trial based on healthy participants aged 18-65 years. PK parameters (AUC 0-∞ , AUC 0-t , and C max ) were assessed using one-way ANOVA and the Power model. Results demonstrated that SA55 injection with a T max of 12.6 days and a half-life of 103 days. In conclusion, the SA55 injection demonstrates potential for use in the prevention of COVID-19 infection.
